SG11201810161RA - Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases - Google Patents

Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases

Info

Publication number
SG11201810161RA
SG11201810161RA SG11201810161RA SG11201810161RA SG11201810161RA SG 11201810161R A SG11201810161R A SG 11201810161RA SG 11201810161R A SG11201810161R A SG 11201810161RA SG 11201810161R A SG11201810161R A SG 11201810161RA SG 11201810161R A SG11201810161R A SG 11201810161RA
Authority
SG
Singapore
Prior art keywords
international
muscle
same
mesenchymal stem
treatment
Prior art date
Application number
SG11201810161RA
Inventor
Chaya Brodie
Shlomit Brodie
Original Assignee
Exostem Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exostem Biotec Ltd filed Critical Exostem Biotec Ltd
Publication of SG11201810161RA publication Critical patent/SG11201810161RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1335—Skeletal muscle cells, myocytes, myoblasts, myotubes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111H11101111111111111111111111111101111111111111111110111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\" WO 2017/199250 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) (72) International Patent Classification: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, C12N 5/0775 (2010.01) A61P 21/00 (2006.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, C12N 5/077 (2010.01) A61K 35/34 (2015.01) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, A61K 35/28 (2015.01) SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, International Application Number: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. PCT/IL2017/050548 (84) Designated States (unless otherwise indicated, for every International Filing Date: kind of regional protection available): ARIPO (BW, GH, 16 May 2017 (16.05.2017) GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Publication Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, Priority Data: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/336,858 16 May 2016 (16.05.2016) US KM, ML, MR, NE, SN, TD, TG). Applicant: EXOSTEM BIOTEC LTD. [IL/IL]; 4 Published: Berkovitch St., 6423806 Tel Aviv (IL). — with international search report (Art. 21(3)) Inventors: BRODIE, Chaya; 17633 Adrian Road, South- — with sequence listing part of description (Rule 5.2(a)) field, Michigan 48075 (US). BRODIE, Shlomit; 49 Ha- choshen Street, 9978500 Nof Ayalon (IL). Agent: KESTEN, Dov et al.; 55 Yigal Alon St., 6789115 Tel Aviv (IL). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, (74) = = _ (81) = = _ = = Title: MESENCHYMAL STEM -ASSOCIATED DISEASES Figure lA 9 = 8 c • ^ c, W C.7 3 ._ F. 'F . 1 -cr) : Isolated cells of a mixed as extracellular vesicles secreted from same, pharmaceutical compositions comprising same, and methods of treatment comprising same, are provided. Further, methods of increasing engraftment of foreign cells by co-administering same are provided. CELL AND USE THEREOF FOR p<0.001 o PBS CD34+ R UC-MSCs • , r ' TREATMENT OF MUSCLE El HC-MSCs , • INJURY AND MUS- — (54) CLE = = = = = = = _ 1-1 0 kin c:7 O Il IN 1-1 0 el (57) well t administering VEGF HIF-1 alpha Utrophin Collagne I NCAM character, possessing a mesenchymal stem cell phenotype and a muscle cell phenotype, as
SG11201810161RA 2016-05-16 2017-05-16 Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases SG11201810161RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662336858P 2016-05-16 2016-05-16
PCT/IL2017/050548 WO2017199250A1 (en) 2016-05-16 2017-05-16 Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases

Publications (1)

Publication Number Publication Date
SG11201810161RA true SG11201810161RA (en) 2018-12-28

Family

ID=60324926

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810161RA SG11201810161RA (en) 2016-05-16 2017-05-16 Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases

Country Status (10)

Country Link
US (2) US10973857B2 (en)
EP (1) EP3458574A4 (en)
JP (1) JP2019514416A (en)
KR (2) KR20220002716A (en)
CN (1) CN109477072A (en)
AU (1) AU2017265937A1 (en)
CA (1) CA3023349A1 (en)
MX (1) MX2018013995A (en)
SG (1) SG11201810161RA (en)
WO (1) WO2017199250A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201810161RA (en) * 2016-05-16 2018-12-28 Exostem Biotec Ltd Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
WO2018211510A1 (en) * 2017-05-16 2018-11-22 Exostem Biotec Ltd. Methods of inhibiting aging and treating aging-related disorders
WO2019169141A1 (en) * 2018-02-28 2019-09-06 Lester Smith Medical Research Institute Production and use of extracellular vesicles
JP2021519283A (en) 2018-03-29 2021-08-10 テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド Vesicles containing PTEN inhibitors and their use
EP3598978A1 (en) 2018-07-26 2020-01-29 EXOFIX S.r.l. Fibroadipogenic progenitor-derived exosomes for regeneration of dystrophic muscles
CN110859854A (en) * 2018-08-08 2020-03-06 上海市东方医院 Pharmaceutical composition for treating neurogenic muscular atrophy and preparation method and application thereof
CN111484978A (en) * 2019-01-28 2020-08-04 深圳市第二人民医院 miR-140-5p overexpression modified human umbilical cord mesenchymal stem cell, and treatment preparation, preparation method and application thereof
AU2020256247A1 (en) * 2019-04-03 2021-10-28 The Johns Hopkins University Methods, compositions, and kits for producing skeletal muscle stem cells and treating disorders
KR102315866B1 (en) * 2020-03-24 2021-10-21 한국원자력의학원 A development of combination therapy for fibrotic diseases
CN111793642B (en) * 2020-07-15 2022-08-05 中山大学孙逸仙纪念医院 Cloning vector for efficiently and stably overexpressing long-chain non-coding RNA and application thereof
CN111850047B (en) * 2020-07-28 2022-08-12 枣庄学院 miR-16 and miR-30c combined expression vector and construction method and application thereof
CN111849878A (en) * 2020-07-30 2020-10-30 陕西佰傲干细胞再生医学有限公司 Method for improving osteogenesis capacity of mesenchymal stem cells
EP4245308A1 (en) * 2020-11-16 2023-09-20 Human Life Cord Japan Inc. Cell preparation to be used for preventing decrease in muscle mass
CN112402439A (en) * 2020-11-18 2021-02-26 西安组织工程与再生医学研究所 Application of miR-325 nucleic acid analogue in preparation of products related to improvement of liver collagen deposition
JP6974892B1 (en) * 2021-05-27 2021-12-01 デクソンファーマシューティカルズ株式会社 Cancer cachexia improving agent and cancer cachexia improving method
CN113750240A (en) * 2021-08-20 2021-12-07 苏州工业园区星湖医院 Application of miR-140-5p inhibitor in preparation of medicine for promoting differentiation of human mesenchymal stem cells
WO2023183860A1 (en) * 2022-03-23 2023-09-28 University Of Delaware Engineered extracellular vesicles for targeted drug delivery to muscle
KR20240002487A (en) * 2022-06-29 2024-01-05 건국대학교 글로컬산학협력단 Composition for preventing or treating muscle inflammation or muscle disease accompanied by inflammation based on pluripotent stem cells
CN116270713B (en) * 2023-03-20 2023-11-07 南方医科大学第三附属医院（广东省骨科研究院） Application of miR-1246 in preparation of medicament for promoting tendon bone healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008546385A (en) * 2005-06-16 2008-12-25 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド Isolated cells and populations containing isolated cells for treating CNS disease
EP2254586B1 (en) * 2008-02-22 2015-04-08 Agency For Science, Technology And Research (A*star) Mesenchymal stem cell particles
CA2780087A1 (en) * 2011-06-14 2012-12-14 Jacques P. Tremblay Myogenic differentiation of stem cells and uses thereof
WO2016057755A1 (en) * 2014-10-09 2016-04-14 Anthrogenesis Corporation Placenta-derived adherent cell exosomes and uses thereof
SG11201810161RA (en) * 2016-05-16 2018-12-28 Exostem Biotec Ltd Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases

Also Published As

Publication number Publication date
US20190125803A1 (en) 2019-05-02
US10973857B2 (en) 2021-04-13
JP2019514416A (en) 2019-06-06
EP3458574A1 (en) 2019-03-27
MX2018013995A (en) 2019-09-18
KR20190007040A (en) 2019-01-21
CN109477072A (en) 2019-03-15
AU2017265937A1 (en) 2018-11-22
US20210228647A1 (en) 2021-07-29
EP3458574A4 (en) 2019-12-25
KR20220002716A (en) 2022-01-06
CA3023349A1 (en) 2017-11-23
WO2017199250A1 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
SG11201810161RA (en) Mesenchymal stem cell and use thereof for treatment of muscle injury and muscle-associated diseases
SG11201810162PA (en) Polynucleotides encoding citrin for the treatment of citrullinemia type 2
SG11201903928WA (en) Mesenchymal stem cells populations, their products, and use thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201805579SA (en) Recombinant igg fc multimers
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809788VA (en) Nanoliposomal irinotecan for use in treating small cell lung cancer
SG11201807593TA (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201808830YA (en) Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
SG11201805311XA (en) Method of treating a mammal, including human, against cancer using methionine and asparagine depletion